Recent commentary around Halozyme Therapeutics (HALO) has centered on its collaborations with large pharmaceutical partners and its use of recombinant human hyaluronidase technology to broaden injectable biologic delivery and expand global reach.

Recent updates around Medicare drug price negotiations and technical trading signals have coincided with Halozyme Therapeutics’ 10.07% 90 day share price return and a 31.03% 1 year total shareholder return, suggesting longer term momentum remains intact despite some near term pullbacks.

If you are looking beyond Halozyme Therapeutics and want more ideas tied to drug delivery and biologics, it could be worth sizing up other healthcare opportunities through the 40 healthcare AI stocks

With Halozyme Therapeutics trading at $69.64, alongside an analyst price target of $83.90 and an indicated intrinsic discount, the key question is whether investors are seeing mispricing today or whether the market already reflects expectations for future growth.

Most Popular Narrative: 18.8% Undervalued

With Halozyme Therapeutics stock at $69.64 against a widely followed fair value estimate of $85.78, the current gap hinges on how investors view its royalty engine and ENHANZE led pipeline.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (e.g., DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Want to understand why this fair value sits well above today's Halozyme Therapeutics share price? The narrative focuses on the impact of compounding royalties, widening margins, and a future earnings base that assumes a different profitability profile to today.

Result: Fair Value of $85.78 (UNDERVALUED)

However, the Halozyme Therapeutics story also carries clear risks, including revenue concentration in a few partner drugs and ongoing patent challenges that could reshape the royalty outlook.

Another View: What Halozyme Therapeutics’ P/E Is Telling You

The earlier narrative references a fair value of $85.78, indicating that Halozyme Therapeutics stock appears undervalued at $69.64. However, on a simple P/E basis of 23.7x, the shares trade above the US Biotechs industry at 16.4x and above the fair ratio of 19.4x. This points to a richer pricing that could limit upside if expectations ease. So which signal should carry more weight in your own work?

For a closer look at how this earnings multiple compares with peers and the fair ratio that the market could move toward, it is worth reviewing the valuation breakdown in detail, beginning with the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of potential rewards and clear risks around Halozyme Therapeutics leaves you undecided, it is worth reviewing the data now and weighing both sides for yourself, starting with the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Halozyme Therapeutics?

If you are serious about building a stronger portfolio, do not stop with Halozyme Therapeutics. Use tools that surface fresh ideas matched to your goals.

• Target potential upside by scanning for quality opportunities trading below their estimated worth through the 44 high quality undervalued stocks
• Strengthen your income stream by focusing on companies offering robust payouts using the 9 dividend fortresses
• Reduce sleepless nights by concentrating on companies with sturdier profiles via the 67 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.